Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.
Endocrine
; 73(3): 641-647, 2021 09.
Article
in En
| MEDLINE
| ID: mdl-33797698
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinolines
/
Thyroid Neoplasms
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Endocrine
Year:
2021
Document type:
Article